L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006
Résumé
Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant toArticle 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSAPanel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on thescientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The foodthat is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine issufficiently characterised. The claimed effect proposed by the applicant is‘normal lipid metabolism’.The target population proposed by the applicant is the general population. The Panel considers thatcontribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes thatthe claim submitted with this application is based on the essentiality of a nutrient. The Panel considersthat the evidence provided does not establish that dietary L-carnitine is required to maintain normallipid metabolism in the target population, for which the claim is intended. The Panel concludes that acause and effect relationship has not been established between the consumption of L-carnitine andcontribution to normal lipid metabolism in the target population.
Domaines
Sciences du Vivant [q-bio]
Fichier principal
EFSA Journal - 2018 - - L‐carnitine and contribution to normal lipid metabolism evaluation of a health claim pursuant to.pdf (571.25 Ko)
Télécharger le fichier
| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|
